LHLabcorp
Price
+14%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, no red flags, price roughly fair, growing in the filings, the market undecided.
Labcorp® Holdings Inc. is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The Company provides insights and accelerates innovations to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. During 2025, the Company’s nearly 71,000 employees served clients in approximately 100 countries and performed more than 750 million tests for patients around the world.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Labcorp (LH) reported revenue of $3.73B in Q2 2026 (quarter ended Jun 30, 2026), up 5.8% from the same quarter a year earlier. That came with a gross margin of 30% and net income of $299M (8.0% of revenue). For the full year FY2025, revenue was $14.0B (+7.2% year on year) and net income $877M. Its largest segment in Q2 2026 was Diagnostics at $2.90B, 78% of the disclosed total, well ahead of Biopharma Laboratory Services at 22%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 30, 2026Labcorp to Announce Third Quarter Financial Results on October 28, 2026.Regulation FD disclosure · press release
- Sep 10, 2026Labcorp Highlights Strategic Priorities Driving Durable Growth.Regulation FD disclosure · press release
- Aug 28, 2026Labcorp to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $3.74BThe company’s own SEC segment disclosure.
- Diagnostics$2.90B78%
- Biopharma Laboratory Services$836.2M22%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
The closest names by size in the same industry